Pacific Biometrics, Inc. (PBI) has been awarded a $1.2 million contract with a top pharmaceutical company related to a biological treatment for rheumatoid arthritis (RA). Under the contract, PBI will provide lab data and autoantibody testing for a global Phase III program. The sponsor plans to submit a NDA with the FDA and equivalent filings with regulatory agencies in other countries. Testing is expected to begin in Q32007 and may extend as long as five years. “Our inclusion in this ...